Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-21

Study Completion Date

2024-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology. The differential diagnosis between the MSA-Parkinsonism (MSA-P) subtype and PD can be very challenging in early disease stages, while early diagnostic certitude is important for the patient because of the diverging prognosis. At the time being, there exists no validated objective biomarker to guide the clinician. Dysarthria is a common early symptom in both diseases and of different origin. The ambition and the originality of this project are to develop a digital voice-based tool for objective discrimination between PD and MSA-P.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis

NCT03577483

Parkinson Disease MSA - Multiple System Atrophy

COMPLETED NA

Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes

NCT02428816

Parkinson's Disease Multiple System Atrophy

COMPLETED NA

Biomarkers in Parkinsonian Syndromes

NCT02114242

Parkinsonian Syndromes Parkinson's Disease Multiple System Atrophy +1 more

RECRUITING

Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison

NCT02753192

Parkinson's Disease Dysarthria Speech +3 more

UNKNOWN NA

Detecting Parkinson's Disease Through Speech Analysis

NCT03133611

Parkinson Disease REM Sleep Behavior Disorder

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The team will build a corpus of voice samples of patients with both diseases and healthy volunteers. This corpus will consist of sustained vowels, pseudo-words, repetition of syllables, utterances of a standard text and spontaneous speech. Voice recordings will be performed using a high quality digital recorder (H4n) and the EVA-2 workstations. EVA-2 is a state-of-the-art system dedicated to pathological voice recording and analysis, which also allows the measurement of aerodynamic features such as intra-oral and subglottal pressure.

An electroglottograph (EGG), a non-invasive device, will also be used in conjunction with the recordings to provide the ground truth of glottal opening and closure instants (OGI and GCI) during utterances. The use of an EGG can be very useful given that OGI and GCI provide valuable information about the voice short-time dynamics.

The team will also perform a laryngostroboscopic examination to highlight defects in vocal cord mobility, a defect in vocal cord mating in phonation, abnormal vocal cord movements or supraglottic structures.

The primary objective is to compare a global score assessing vocal performance between MSA-P, PD and healthy volunteers. Secondary objectives are 1) to compare an acoustic index, assessing the subsystems of speech production, between MSA-P, PD and healthy volunteers, 2) to compare an acoustic index, assessing types of dysarthria, between MSA-P and PD patients, and 3) to compare perceptual assessment, performed by a panel of experts, of voice alteration between MSA-P and PD patients.

The final goal of this study is to evaluate the validity of the vocal markers that were identified in the previous study (Voice4PD-MSA-I, exploratory cohort). The validation will only consider data collected in the present study in order to assess the performance of the classifiers developed in the exploratory cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Multiple System Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's disease

Diagnosis of idiopathic Parkinson's disease (PD) according to MDS criteria (Postuma et al., 2015)

Group Type EXPERIMENTAL

voice recordings

Intervention Type PROCEDURE

A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Multiple system atrophy parkinsonian subtype (MSA-P)

Diagnosis of Multiple Atrophy System (MSA-P) Parkinsonian form possible or probable according to consensus criteria (Gilman et al., 2008)

Group Type EXPERIMENTAL

voice recordings

Intervention Type PROCEDURE

A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Healthy volunteer

Absence of neurologic and oto-rhino-laryngologic disease

Group Type EXPERIMENTAL

voice recordings

Intervention Type PROCEDURE

A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

voice recordings

A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 30 to 80 years old
* Signed informed consent
* Affiliated to social security
* Patient with PD :

* Diagnosis of idiopathic Parkinson's disease (PD) according to criteria (Postuma et al., 2015)
* Patient PD : Hoehn\&Yahr stage between 1 and 2
* Patient with or without mild to moderate speech troubles: MDS-UPDRS III item 1 ≤ 2
* Patients with MSA-P :

* Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to current consensus criteria (Gilman et al., 2008)
* Patient MSA-P: score of part IV of the UMSARS ≤ 3 points
* Patient with or without mild to moderate speech troubles: UMSARS II item 2 ≤ 2
* Controls :

* Absence of neurologic and oto-rhino-laryngologic disease